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state, the patient is predisposed to recurrent
infection and current antimicrobial protocols for
the treatment of IE may need to be reviewed.
Alternatively, the bacterial DNA detected may
represent non-viable artefacts of the original
infection. The failure to detect microorganism
DNA within tissues removed several years after
infection supports this hypothesis. The persist-
ence of bacterial debris may be driving a con-
tinued sub-clinical immune response, leading to
further inﬂammation and damage to the valve. It
remains an intriguing possibility that a number
of patients, who have been treated successfully
for IE previously, may require surgical replace-
ment of a valve because of inﬂammatory damage
that has arisen from the persistence of bacterial
debris. These ﬁndings also have implications for
the diagnostic use of PCR in patients with a
history of previous infection.
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ABSTRACT
The in-vivo activity of colistin was evaluated in an
experimental rabbit model of Acinetobacter bau-
mannii endocarditis with a strain susceptible to
colistin and intermediate to imipenem. Compared
to a control group, colistin was effective (p < 0.05)
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in bacterial clearance from blood and in the
sterilisation of blood cultures, but was not effect-
ive in clearing A. baumannii from vegetations.
Thus, although colistin may be effective in treat-
ing bacteraemia caused by susceptible strains of
A. baumannii, it may not be a suitable treatment
for endocarditis, perhaps because of poor penet-
ration into vegetations and a low Cmax ⁄MIC ratio
in tissue.
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istin, endocarditis
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Acinetobacter baumannii is a frequent cause of
nosocomial infections, particularly pneumonia
and bacteraemia, with respiratory tract infections,
surgical site infections and infections associated
with intravascular catheters being the most com-
mon sources [1]. A. baumannii bacteraemia is
associated with a high mortality rate [1]. Many
nosocomial strains of A. baumannii have now
developed resistance against multiple antimicro-
bial agents, including imipenem, but have
remained susceptible to colistin [2,3]. Several
reports have described the successful treatment
of infections caused by imipenem-resistant
A. baumannii with colistin [4–7], but there are no
data on the efﬁcacy of colistin for treatment of
A. baumannii bacteraemia. The aim of the present
study was to evaluate the in-vitro and in-vivo
activity of colistin in an experimental rabbit
model of A. baumannii endocarditis with a strain
susceptible to colistin and intermediately suscep-
tible to imipenem.
In-vitro studies were performed with an
A. baumannii strain (imipenem MIC of 8 mg ⁄L)
isolated from blood cultures and identiﬁed by
the MicroScan system (Baxter Health Care, West
Sacramento, CA, USA), the API 20NE system
(bioMe´rieux, Marcy l’Etoile, France) and stand-
ard growth tests. Colistin MICs were measured
by the tube dilution method over the range 0.06–
128 mg ⁄L, with a ﬁnal bacterial concentration of
5 · 105 CFU ⁄mL. Escherichia coli strain ATCC
25922 was used as a control strain. The MIC
was deﬁned as the lowest concentration of
antibiotic at which no growth was visible
to the naked eye. The minimum bactericidal
concentration (MBC) was deﬁned as the lowest
concentration of antibiotic which resulted in the
killing of 99.9% of the original inoculum. The
in-vitro bactericidal activity was evaluated by
time-killing curves with 20 mL of Mueller–Hin-
ton broth, an inoculum of 5 · 105 CFU ⁄mL, and
colistin concentrations equivalent to the Cmax in
rabbits (see below). Viable counts were deter-
mined at 0, 2, 4, 8 and 24 h. The antibiotic was
considered bactericidal when a 3 · log10 de-
crease in the viable count compared to the initial
inoculum was achieved.
In-vivo studies were performed in immuno-
competent New Zealand rabbits weighing
2–3 kg (BK Universal, Barcelona, Spain). The
experimental A. baumannii endocarditis model
reported previously was used [8]. Four days
after insertion of an intracardiac catheter in
the left ventricle, the rabbits were inoculated
with 1 mL of an A. baumannii suspension
(108 CFU ⁄mL) through the marginal vein of the
ear. Blood samples were taken 24 h after inocu-
lation to conﬁrm the onset of endocarditis. At
this time, the rabbits were divided into two
groups. The control group (n = 12) did not
receive antimicrobial treatment, while the second
group (n = 10) received treatment with two
doses of intramuscular colistin, 5 mg ⁄ kg, separ-
ated by 12 h (Fig. 1). Further blood samples
were taken from all surviving rabbits 48 h after
inoculation (Fig. 1). This was done through the
marginal vein of the ear, with viable counts
determined on Columbia sheep blood agar
plates following incubation for 24 h at 37C.
All surviving rabbits were killed humanely 48 h
after inoculation (Fig. 1). Following thoracotomy,
the heart valves were dissected aseptically and
weighed. The valves were homogenised (Stoma-
cher 80; Tekmar, Cincinnati, OH, USA) for 2 min
in 1 mL of sterile saline solution, and this was
followed by determination of viable counts as
described above. Cultures showing no growth
were assigned a value corresponding to the
sensitivity level of the method (i.e., 1 CFU). The
Mann–Whitney U-test and Fisher’s test were
used to compare the mean viable counts in the
vegetations and blood, as well as the number of
sterile cultures. A p value of < 0.05 was
considered signiﬁcant. In order to conﬁrm that
colistin itself was not toxic, a group of non-
infected rabbits (n = 6) was given the antibiotic
for 24 h (non-infected treated group).
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Plasma colistin levels were determined after the
administration of 5 mg ⁄kg in a single intramus-
cular dose. After 10, 15, 30, 60, 120, 240 and
480 min, blood was extracted from the marginal
vein of the ear, using ﬁve rabbits at each time-
point. Drug concentrations in plasma were meas-
ured by a broth dilution assay using E. coli strain
ATCC 25922. The maximum concentration (Cmax,
mg ⁄L), the area under the concentration–time
curve (AUC, mg.h ⁄L), the terminal half-life
(t1 ⁄ 2, h) and the time for which the plasma
concentration remained above the MIC (t ⁄MIC,
h) were determined.
The colistin MIC and MBC for the A. baumannii
strain used were both 2 mg ⁄L. In time-kill experi-
ments, colistin showed bactericidal activity after
2 h at concentrations equivalent to Cmax in the
rabbits. The pharmacokinetic ⁄pharmacodynamic
parameters for a dose of 5 mg ⁄ kg were: Cmax,
9 mg ⁄L; t½, 03.08 h; AUC, 41.72 mgh ⁄L; t ⁄MIC,
07.43 h; and Cmax ⁄MIC, 4.5.
In the control group, 11 (92%) of the 12 rabbits
survived for 48 h after inoculation. A. baumannii
was isolated from all blood cultures obtained 24 h
after inoculation and before killing. A. baumannii
was also isolated from all the valves (Table 1). In
the colistin-treated group, survival was 100%. All
rabbits were bacteraemic 24 h after inoculation,
with similar viable counts to the control group
(Table 1). Following colistin treatment, only two
(20%) of the rabbits remained bacteraemic
(p < 0.05), and there was also a signiﬁcant differ-
ence in the viable counts compared with the
control group (p < 0.05; Table 1). No growth was
obtained from the heart valves of four (40%) of
the rabbits treated with colistin, but there were no
signiﬁcant differences compared to the control
group (Table 1). The survival rate was 100% in
the non-infected treated control group.
Overall, colistin was bactericidal in vitro against
A. baumannii at the Cmax reached in the rabbit
plasma at any time evaluated. This concentration
was equivalent to 4.5 · MIC for the strain used in
the experiments. These results are in accordance
with those from a previous study that investi-
gated 39 strains of multiresistant A. baumannii, all
susceptible to colistin (MIC90 £ 1 mg ⁄L) [9]. In
this previous study, colistin was bactericidal in
time-kill experiments after 2 and 4 h at 1 · MIC,
and at 2, 4 and 6 h at 4 · MIC [9]. However, other
authors have investigated A. baumannii strains
with colistin MICs of 0.5 mg ⁄L and MBCs of 0.5–
2 mg ⁄L, and reported bactericidal activity only at
16 · MIC and 32 · MIC [10]. These results sug-
gest that the in-vitro bactericidal activity of
colistin is strain- and dose-dependent.
In the present study, colistin was active in vivo
in the treatment of bacteraemia in the rabbit
model, reducing the number of CFU ⁄mL and
resulting in 80% of blood cultures being negative.
These results are in accordance with the in-vitro
bactericidal activity. The bactericidal activity of
(a)
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Fig. 1. Time course of the in-vivo
study. (a) Control group of rabbits.
(b) Colistin-treated group of rabbits.
The colistin-treated group of rab-
bits received two doses of intra-
muscular colistin at the time-points
indicated. Viable counts of A. bau-
mannii in blood cultures (BC) and
heart valves recovered from survi-
ving rabbits were determined at the
time-points indicated.
Table 1. Effect of colistin therapy
on the clearance of Acinetobacter
baumannii from heart valves and
blood
Treatment (n)
Valves
log10 CFU/g
(means ± SD)
Valves
no. sterile/
no. analysed (%)
Blood
log10 CFU/mL
(means ± SD)
Blood
no. sterile/
no. blood cultures (%)
Control (12) 6.32 ± 1.81 0 ⁄ 11 (0) 2.74 ± 0.97 0 ⁄ 11 (0)
Colistin (10) 4.69 ± 2.09 4 ⁄ 10 (40) 1.37 ± 0.83a 8 ⁄ 10 (80)a
ap < 0.05 compared to the control group.
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colistin results from a concentration-dependent
detergent effect on the cell membrane [11], so the
most important pharmacokinetic ⁄pharmacody-
namic parameter describing this activity is Cmax ⁄
MIC [12], which was 4.5 for rabbit plasma in the
present study. In a mouse model of experimental
A. baumannii pneumonia, colistin was effective in
reducing the rate of bacteraemia in mice for both
imipenem-susceptible and -resistant strains [10].
Bacterial blood clearance in the present study was
higher than that achieved with imipenem and
sulbactam (10% and 22% of negative blood
cultures, respectively) in the A. baumannii endo-
carditis model [8], although the strain used
previously was intermediate to both b-lactams.
However, colistin did not reduce the bacterial
counts in vegetations. In contrast, imipenem is
active in lowering the A. baumannii cell count in
blood and valves [8]. Thus, penetration of colistin
into vegetations may not reach a bactericidal
concentration, and the Cmax ⁄MIC ratio in vegeta-
tions may be lower than in plasma, thereby
explaining the difference between results for
blood and vegetations. Similarly, in the experi-
mental A. baumannii pneumonia model, colistin
was ineffective in reducing mortality and clearing
bacteria from lungs, perhaps caused by poor
tissue penetration of colistin [10].
Clinical experience with colistin is limited to
case reports describing successful treatment of
pneumonia [5], ventriculitis and meningitis [4,6,7]
caused by carbapenem-resistant A. baumannii
strains. In a case of meningitis treated successfully
with intravenous colistin [7], the pharmacokinetic
proﬁle of colistin in cerebrospinal ﬂuid (Cmax of
1.25 mg ⁄L and Cmax ⁄MIC ratio of 4) was similar
to that obtained in plasma in the present study.
In conclusion, the results of this study suggest
that colistin is effective in the clearance of
A. baumannii bacteraemia caused by susceptible
strains. However, the data also suggest that
colistin may not be a suitable treatment for
endocarditis. The possible use of colistin for
treatment of organ infections caused by A. bau-
mannii requires further data concerning tissue
concentrations with different doses in experimen-
tal models in order to determine appropriate
Cmax ⁄MIC ratios.
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